# TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

Source: https://onco.cc/trials/nct02641847/  
OnCo record `nct02641847` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of docetaxel, doxorubicin, epirubicin, cyclophosphamide and other drugs in triple-negative breast cancer, run by Fudan University, active but no longer recruiting.

## Summary

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature is a phase 2/3, randomised interventional study registered as NCT02641847 by Fudan University, with a registry enrolment figure of 503 participants, started 2016-01 and due to reach its primary completion in 2023-12. Interventions recorded: docetaxel; doxorubicin or epirubicin; cyclophosphamide; gemcitabine; cisplatin. Conditions listed: Triple Negative Breast Cancer; Breast Cancer. Triple-negative eligibility wording from the registry: "Triple negative breast cancer confirmed by pathology". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT02641847
- Phase: 2/3
- Setting: Efficacy and Safety Study of TA(E)C-GP Versus A(E)C-T for the High Risk Triple-negative Breast Cancer Patients Predicted by the Messenger RNA (mRNA)-Long Non-coding RNA (lncRNA) Signature and Validation of the Signature's Efficacy
- Sponsor: Fudan University
- Enrolled: 503

## Sources

- ClinicalTrials.gov NCT02641847: https://clinicaltrials.gov/study/NCT02641847

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Cyclophosphamide](https://onco.cc/drugs/cyclophosphamide/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Epirubicin](https://onco.cc/drugs/epirubicin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct02641847.json